{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:59Z","timestamp":1792699979344,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.psychres.2020.113249","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T03:08:06Z","timestamp":1592881686000},"page":"113249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database"],"prefix":"10.1016","volume":"291","author":[{"given":"Masakazu","family":"Hatano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Shimato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2020.113249_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/pcn.12793","article-title":"Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database","volume":"73","author":"Anzai","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2020.113249_bib0002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psychres.2004.11.002","article-title":"A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia.","volume":"133","author":"Byerly","year":"2005","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2020.113249_bib0003","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","article-title":"A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data","volume":"35","author":"Cornelius","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.psychres.2020.113249_bib0004","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/schbul\/sbv001","article-title":"The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings","volume":"41","author":"de Boer","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2020.113249_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2003.11.001","article-title":"Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia","volume":"70","author":"Eerdekens","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2020.113249_bib0006","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/0269881105057001","article-title":"Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia","volume":"20","author":"Ezewuzie","year":"2006","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2020.113249_bib0007","first-page":"132","article-title":"[What Lessons Should We Learn from the Death of Patients on Xeplion?]","volume":"117","author":"Fujii","year":"2015","journal-title":"Seishin Shinkeigaku Zasshi"},{"key":"10.1016\/j.psychres.2020.113249_bib0008","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"Br. Med. J."},{"key":"10.1016\/j.psychres.2020.113249_bib0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113249_bib0010","article-title":"Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases","volume":"3","author":"Hatahira","year":"2017","journal-title":"J. Pharm. Heal. Care Sci."},{"key":"10.1016\/j.psychres.2020.113249_bib0011","doi-asserted-by":"crossref","first-page":"132","DOI":"10.9758\/cpn.2017.15.2.132","article-title":"Assessment of the latent adverse events of antipsychotic treatment using a subjective questionnaire in Japanese patients with schizophrenia","volume":"15","author":"Hatano","year":"2017","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.psychres.2020.113249_bib0012","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113249_bib0013","article-title":"Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports","volume":"1","author":"Kato","year":"2015","journal-title":"J. Pharm. Heal. Care Sci."},{"key":"10.1016\/j.psychres.2020.113249_bib0014","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113249_bib0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2020.113249_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1248\/yakushi.16-00219","article-title":"Evaluation of the expression profile of extrapyramidal symptoms due to antipsychotics by data mining of Japanese adverse drug event report (JADER) database","volume":"137","author":"Kose","year":"2017","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.psychres.2020.113249_bib0017","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","author":"Lacro","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113249_bib0018","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","author":"Leucht","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.psychres.2020.113249_bib0019","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2013.06.041","article-title":"Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study","volume":"150","author":"Mallikaarjun","year":"2013","journal-title":"Schizophr. Res."},{"issue":"Suppl 5","key":"10.1016\/j.psychres.2020.113249_bib0020","first-page":"15","article-title":"Risks versus benefits of different types of long-acting injectable antipsychotics","volume":"67","author":"McEvoy","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113249_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200505000-00001","article-title":"Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2020.113249_bib0022","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","year":"2015","journal-title":"J. Pharm. Heal. Care Sci."},{"key":"10.1016\/j.psychres.2020.113249_bib0023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40264-013-0032-z","article-title":"Antipsychotics and torsadogenic risk: signals emerging from the US FDA adverse event reporting system database","volume":"36","author":"Poluzzi","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.psychres.2020.113249_bib0024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113249_bib0025","doi-asserted-by":"crossref","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.psychres.2020.113249_bib0026","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.psychres.2020.113249_bib0027","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/YIC.0b013e3280119ddb","article-title":"Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone","volume":"22","author":"Schmauss","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2020.113249_bib0028","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2020.113249_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/17512433.2017.1345623","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone","author":"Schoretsanitis","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2020.113249_bib0030","article-title":"Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study 11 Medical and Health Sciences 1103 Clinical Sciences","volume":"18","author":"Sch\u00f6ttle","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2020.113249_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","author":"Stroup","year":"2018","journal-title":"World Psychiatry."},{"key":"10.1016\/j.psychres.2020.113249_bib0032","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2020.113249_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection is spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.psychres.2020.113249_bib0034","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.4088\/JCP.16m11308","article-title":"Does half-life matter after antipsychotic discontinuation? a relapse comparison in schizophrenia with 3 different formulations of paliperidone","volume":"78","author":"Weiden","year":"2017","journal-title":"J. Clin. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120316292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120316292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:45:07Z","timestamp":1759038307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178120316292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"alternative-id":["S0165178120316292"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113249","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113249"}}